Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caris Life Sciences (CAI) Change in Accured Expenses (2024 - 2025)

Caris Life Sciences (CAI) has 2 years of Change in Accured Expenses data on record, last reported at $29.3 million in Q4 2025.

  • For Q4 2025, Change in Accured Expenses rose 97.46% year-over-year to $29.3 million; the TTM value through Dec 2025 reached $28.5 million, changed N/A, while the annual FY2025 figure was $11.5 million, 1329.51% up from the prior year.
  • Change in Accured Expenses reached $29.3 million in Q4 2025 per CAI's latest filing, up from $889000.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $29.3 million in Q4 2025 and bottomed at -$16.4 million in Q3 2024.